| Phrase | Consultant | Town | Special Interests |
| Benign and malignant laryngeal oropharyngeal thyroid and salivary gland disease | *Consultant(s)* | *Towns* | Benign and malignant laryngeal oropharyngeal thyroid and salivary gland disease |
| core and swallowing outcomes in late phase clinical trials involving patients with OPSCC - oropharyngeal squamous cell carcinoma | *Consultant(s)* | *Towns* | Early phase clinical trials, the role of the p53/MDM2 pathway in radioresistance and cellular motility, the therapeutic exploitation of the unfolded protein response in head and neck cancer, treatment response in HPV - human papilloma virus +ve oropharyngeal cancer intraoperative radiotherapy, core and swallowing outcomes in late phase clinical trials involving patients with OPSCC - oropharyngeal squamous cell carcinoma, function sparing surgical strategies for head and neck cancer - especially transoral laser microsurgery |
| Oral and oropharyngeal cancer | *Consultant(s)* | *Towns* | Oral and oropharyngeal cancer, facial trauma, facial skin cancer, salivary gland disease, cosmetic surgery |
| oral and oropharyngeal oncology | *Consultant(s)* | *Towns* | Dentoalveolar surgery, oral medicine, salivary gland disease, oral and oropharyngeal oncology, head and neck skin malignancy, head and neck reconstructive surgery |
| oropharyngeal cancer | *Consultant(s)* | *Towns* | Clinical oncology, soft tissue and bone sarcomas, oropharyngeal cancer, laryngeal/hypopharyngeal cancer, head and neck sarcomas, salivary gland cancers, gastrointestinal stromal tumours - GIST, late radiotherapy toxicity, survivorship - resilience for patients |
| oropharyngeal cancers | *Consultant(s)* | *Towns* | Head and neck surgery, oropharyngeal cancers, laryngeal malignancies, thyroid diseases, swellings |
| Recurrent oral and oropharyngeal squamous cell carcinoma - OPSCC | *Consultant(s)* | *Towns* | Recurrent oral and oropharyngeal squamous cell carcinoma - OPSCC, facial plastic surgery |
| treatment response in HPV - human papilloma virus +ve oropharyngeal cancer intraoperative radiotherapy | *Consultant(s)* | *Towns* | Early phase clinical trials, the role of the p53/MDM2 pathway in radioresistance and cellular motility, the therapeutic exploitation of the unfolded protein response in head and neck cancer, treatment response in HPV - human papilloma virus +ve oropharyngeal cancer intraoperative radiotherapy, core and swallowing outcomes in late phase clinical trials involving patients with OPSCC - oropharyngeal squamous cell carcinoma, function sparing surgical strategies for head and neck cancer - especially transoral laser microsurgery |
